← Back to Screener
Ascendis Pharma A/S American Depositary Shares (ASND)
Price$242.95
Favorite Metrics
Price vs S&P 500 (26W)11.04%
Price vs S&P 500 (4W)0.47%
Market Capitalization$17.47B
All Metrics
P/CF (Annual)233.81x
Book Value / Share (Quarterly)$1.33
P/TBV (Annual)22.12x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)141.43%
Cash Flow / Share (Quarterly)$0.86
Price vs S&P 500 (YTD)10.71%
Gross Margin (TTM)86.82%
Net Profit Margin (TTM)-31.67%
EPS (TTM)$-4.40
10-Day Avg Trading Volume0.67M
EPS Excl Extra (TTM)$-4.40
Revenue Growth (5Y)152.98%
EPS (Annual)$-4.43
ROI (Annual)-75.57%
Gross Margin (Annual)86.82%
Net Profit Margin (5Y Avg)-1277.24%
Cash / Share (Quarterly)$11.71
Revenue Growth QoQ (YoY)42.31%
ROA (Last FY)-17.51%
Revenue Growth TTM (YoY)98.03%
EBITD / Share (TTM)$-2.21
ROE (5Y Avg)-79.56%
Operating Margin (TTM)-18.92%
Cash Flow / Share (Annual)$0.86
P/B Ratio194.47x
P/B Ratio (Quarterly)67.07x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)17.85x
Net Interest Coverage (TTM)-1.78x
ROA (TTM)-19.80%
EPS Incl Extra (Annual)$-4.43
Current Ratio (Annual)1.04x
Quick Ratio (Quarterly)0.72x
3-Month Avg Trading Volume0.69M
52-Week Price Return55.44%
EV / Free Cash Flow (Annual)283.13x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.24
P/S Ratio (Annual)17.50x
Asset Turnover (Annual)0.55x
52-Week High$250.74
Operating Margin (5Y Avg)-1434.27%
EPS Excl Extra (Annual)$-4.43
CapEx CAGR (5Y)-17.01%
Tangible BV CAGR (5Y)7.07%
26-Week Price Return15.03%
Quick Ratio (Annual)0.72x
13-Week Price Return15.78%
Total Debt / Equity (Annual)1.93x
Current Ratio (Quarterly)1.04x
Enterprise Value$15,144.028
Revenue / Share Growth (5Y)144.03%
Asset Turnover (TTM)0.63x
Book Value / Share Growth (5Y)-1.87%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.32x
Pretax Margin (Annual)-29.53%
Cash / Share (Annual)$11.71
3-Month Return Std Dev39.63%
Gross Margin (5Y Avg)77.81%
Net Income / Employee (TTM)$-0
ROE (Last FY)-221.49%
Net Interest Coverage (Annual)0.20x
EPS Basic Excl Extra (Annual)$-4.43
Receivables Turnover (TTM)4.68x
EV / Free Cash Flow (TTM)283.13x
Total Debt / Equity (Quarterly)7.81x
EPS Incl Extra (TTM)$-4.40
Receivables Turnover (Annual)4.68x
ROI (TTM)-80.63%
P/S Ratio (TTM)17.50x
Pretax Margin (5Y Avg)-1274.82%
Revenue / Share (Annual)$13.99
Tangible BV / Share (Annual)$5.39
Forward P/E50.01x
Price vs S&P 500 (52W)25.61%
Year-to-Date Return13.35%
5-Day Price Return0.00%
EPS Normalized (Annual)$-4.43
ROA (5Y Avg)-39.35%
Net Profit Margin (Annual)-31.67%
Month-to-Date Return5.67%
Cash Flow / Share (TTM)$-13.39
EBITD / Share (Annual)$-2.24
Operating Margin (Annual)-18.92%
LT Debt / Equity (Annual)1.83x
P/CF (TTM)233.81x
ROI (5Y Avg)-48.05%
LT Debt / Equity (Quarterly)7.40x
EPS Basic Excl Extra (TTM)$-4.40
P/TBV (Quarterly)72.19x
P/B Ratio (Annual)22.01x
Inventory Turnover (TTM)0.32x
Pretax Margin (TTM)-29.53%
Book Value / Share (Annual)$5.42
Price vs S&P 500 (13W)15.10%
Beta0.45x
P/FCF (Annual)277.50x
Revenue / Share (TTM)$13.86
ROE (TTM)-257.14%
52-Week Low$150.89
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ASNDAscendis Pharma A/S American Depositary Shares | 17.50x | 98.03% | 86.82% | — | $242.95 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Ascendis Pharma is a biopharmaceutical company that develops therapeutics using its proprietary TransCon technology platform, with a pipeline focused on endocrinology and oncology indications including TransCon PTH and TransCon CNP. The company primarily generates revenue from the United States, with operations across Europe and international markets.